The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes
    • The Product Book

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
    • Content Hubs
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2026 / November / Salivary Proteomics Reveals Protein Changes During Multiple Sclerosis Treatment
Mass Spectrometry Liquid Chromatography News and Research

Salivary Proteomics Reveals Protein Changes During Multiple Sclerosis Treatment

An exploratory study found disease- and therapy-associated patterns in saliva, offering candidate markers for further investigation

11/16/2026 2 min read

Share

Salivary proteomics has identified molecular patterns associated with relapsing-remitting multiple sclerosis (RRMS) and changes occurring during disease-modifying therapy, suggesting that saliva could provide a noninvasive sample for studying molecular changes over time.

The exploratory study compared saliva samples from 66 patients with RRMS before starting a new therapy with samples from 31 healthy controls. 40 patients provided a second sample after six months of treatment.

Researchers from the University of Cagliari and collaborating institutions analyzed the samples using nano-liquid chromatography coupled with high-resolution tandem mass spectrometry. The workflow used an LTQ Orbitrap Elite instrument and label-free quantification based on precursor-ion areas.

The analysis identified 1,305 proteins after contaminants were removed. Of these, 623 met the criteria for statistical analysis, and 209 differed significantly across the main comparisons.

Before treatment, 116 proteins differed in abundance between patients with RRMS and healthy controls. After six months of therapy, 54 proteins remained different between the patient and control groups. The researchers interpreted this reduction as evidence of changing salivary protein patterns, rather than proof of treatment response.

Further analysis identified several types of molecular pattern. 28 proteins remained altered at both patient time points, indicating persistent RRMS-associated differences. Another 38 shifted toward the levels observed in healthy controls after six months, while 25 became significantly different only at follow-up. Paired analysis also detected 36 proteins that changed within individual patients but did not differ significantly from controls at either time point.

Pathway enrichment linked many of the altered proteins to innate immunity, neutrophil degranulation, cytokine signaling, programmed cell death, and protein folding. Proteins associated with inflammatory pathways moved toward control levels after treatment.

The researchers also identified a 50-protein panel that distinguished healthy controls, patients before treatment, and patients after six months of therapy within the study cohort.

The authors therefore caution that the protein panel is not ready for diagnostic or clinical use. Its current value lies in identifying candidate markers and demonstrating an analytical strategy for monitoring molecular changes through repeated, noninvasive sampling. Larger multicenter studies will need to compare salivary signatures with clinical findings, imaging, and established fluid biomarkers.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

 This Week’s Mass Spec News
Mass Spectrometry
This Week’s Mass Spec News

April 4, 2025

2 min read

 What If Computers Could Smell?
Mass Spectrometry
What If Computers Could Smell?

April 3, 2025

13 min read

Computers can “see” and “hear,” but fully digitizing scent has so far eluded science – but that may soon change

The Analytical Scientist Innovation Awards 2024: #6
Mass Spectrometry
The Analytical Scientist Innovation Awards 2024: #6

December 3, 2024

3 min read

Syft Technologies’ William Pelet introduces the Syft Explorer – the world's first fully mobile, real-time, and direct trace gas analyzer

The Analytical Scientist Innovation Awards 2024: #4
Mass Spectrometry
The Analytical Scientist Innovation Awards 2024: #4

December 5, 2024

6 min read

Thermo Fisher Scientific’s high-sensitivity mass spec for translational omics research – the Stellar MS – is ranked 4th in our annual Innovation Awards

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.